Emerging treatments in Multiple myeloma. Josh Veatch Damian Green
|
|
- Cameron Barker
- 5 years ago
- Views:
Transcription
1 Emerging treatments in Multiple myeloma Josh Veatch Damian Green
2 Emerging treatments in multiple myeloma Introduction Daratumumab Elotuzumab PD 1 inhibitors HDAC inhibitors Other emerging therapies in early trials and development
3 Multiple myeloma Plasma cell neoplasm Disease manifestations Lytic bone lesions Hypercalcemia Marrow failure Paraprotein mediated effects renal failure Immunoparesis Outcomes have significantly improved with IMiDs and proteasome inhibitors, but no curative treatments Until recently no rituximab for myeloma
4 Ixazomib Chari, Ajai. "Novel Targets in Multiple Myeloma." American Journal of Hematology/Oncology 11.3 (2015).
5 Daratumumab Humanized antibody to CD38, a surface marker on multiple myeloma Induces cell killing through either complement or antibody dependent cellular toxicity. The Journal of Immunology February 1, 2011 vol. 186 no
6
7 Lokhorst HM et al. N Engl J Med 2015;373:
8 Daratumumab in combination therapy 498 patients with relapsed/refractory myleoma Bortezomib/dexamethasone for 8 cycles with half randomized to 16mg/kg Daratumumab followed by daratumumab maintenance PFS was primary endpoint, TTP, ORR and OS were secondary endpoints Median 2 prior lines of therapy, 76% with prior Imids, 48% with prior proteoasome inhibitor and IMiDs, 33% refractory to past therapy J Clin Oncol 34, 2016 (suppl; abstr LBA4)
9 journal/news/clinical/clinical pharmacology/therapeuticconsiderations managing multiple m
10 VD +/ Daratumumab ORR CR VGPR or better Daratumumab 83% 19% 59% Control 63% 9% 29% Thrombocytopenia Neuropathy Diarrhea anemia Daratumumab 59% 47% 32% 26% Control 44% 38% 22% 31% J Clin Oncol 34, 2016 (suppl; abstr LBA4)
11 Daratumumab +VD VD PFS Median, mo NE 7.16 HR (95% CI) 0.39 (0.28, 0.53) TTP P < Median, mo NE 7.29 HR (95% CI) 0.30 (0.21, 0.43) P < J Clin Oncol 34, 2016 (suppl; abstr LBA4)
12 Daratumumab FDA Approved as monotherapy With superior responses when combined with Bortezomib/Dex in relapsed/refractory disease Validation of CD38 as a target in multiple myeloma
13 Elotuzumab Monoclonal antibody directed at CS1 (SLAMF7) Surface marker on myeloma cells Also found on natural killer cells Limited/no activity as a single agent Much more activity when combined with lenalidomide Approved only as a combination therapy with lenalidomide
14 Characteristics of the Patients at Baseline (Intention-to-Treat Population). Lonial S et al. N Engl J Med 2015;373:
15 Lonial S et al. N Engl J Med 2015;373:
16 Lonial S et al. N Engl J Med 2015;373:
17 Lonial S et al. N Engl J Med 2015;373: Adverse Events
18 of action
19 Actual mechanism different from intended mechanism No drug to stupid to test Maybe we should just develop drugs at random hoping that they happen to activate natural killer cells
20 Chari, Ajai. "Novel Targets in Multiple Myeloma." American Journal of Hematology/Oncology 11.3 (2015).
21 Monoclonal antibody summary CD38 is a validated target in multiple myeloma Daratumumab SAR (Isatuximab) CS1/SLAMF7 is also a target, but possibly for different mechanisms Elotuzumab Other targets CD138 PD 1
22 PD 1 inhibition Leukemia (2016) 30, ; doi: /leu
23 Pembrolizumab with activity when combined with lenalidomide J Clin Oncol 34, 2016 (suppl; abstr 8010)
24 Pembrolizumab with activity when combined with lenalidomide Many responses ongoing with median follow up of 9 months Combination was tolerated with some immune adverse events Phase III trial enrolling now J Clin Oncol 34, 2016 (suppl; abstr 8010)
25 HDAC inhibitors Histone deacetylase inhibitors change marks on chromatin that modify gene expression, also modify acetylation of other proteins They have activity in many malignancies They are about as targeted as total body irradiation, digitalis Some thought that the important function in myeloma is due to the HDAC6 mediated induction of the aggresome, or of HDAC6 induction of oncogene expression
26 Chari, Ajai. "Novel Targets in Multiple Myeloma." American Journal of Hematology/Oncology 11.3 (2015).
27 HDAC inhibitors Nonspecific HDAC inhibitors have some modest efficacy in combinations, but at the cost of significant toxicity Diarrhea, fatigue, thrombocytopenia More targeted HDAC inhibitors (Ricolinostat) may be effective with less toxicity, but await randomized trials
28 Other targeted agents KSP1 mitotic spindle regulator AKT involved in mtor/growth signalling PIM kinase XPO1 nuclear exportin
29 Chari, Ajai. "Novel Targets in Multiple Myeloma." American Journal of Hematology/Oncology 11.3 (2015).
30 What s in preclinical development? CAR T cell targeted at CD19 Single response at UPENN resulted in a NEJM paper Subpopulation of cells expressing CD19? Or low threshold for CD19 level needed No responses among plasma cell neoplasm patients treated here with CD19 CAR BITE targeted at BCMA Currently in phase I trials CAR T cells targeted at BCMA 2 responses of marrow disease on highest dose level with typical cytokine release syndrome seen in CD19 CAR
31 Srivastava and Riddell, Trends in immunology (2016)
32 BCMA CAR T cell trial at the NCI with clinical responses 10 patients treated in a dose escalation 2 VGPR and 1CR 1 VGPR and 1CR of two patients treated at highest dose level Patients had cytokine release syndrome at highest dose level
33 A Human NSG mouse Xenograft model of Myeloma Anti-Tumor efficacy of BCMA-specific T-cells in RPMI 8226 ffluc tumor bearing NSG Day 0 T cell Injection 50:50 :: CD8:CD4 1.1E6 C113ST 2.3E6 C113ST 4.5E6 C113ST 10wk old NSG Males Day Rads Day 7 2 x 2.5E cells 4.3E6 tegfr Tyler Hill, Riddell Lab
34 1 million CARs 4 million CARs 4 million Control Day 0 Anti BCMA CAR T cells are effective against myeloma in a Xenograft model Day 9 Day 24 Day 44 Tyler Hill, Riddell Lab
35 Summary 2 new approved monoclonal antibodies A number of different new agents with modest single agent activity in refractory disease Emerging targeted immunotherapy coming soon to a clinical trial at our center
36 Thanks Fellowship/hematology Abbe Lynch Mark Albonizio Emerson Lynch Mike Linenberger Evan Yu Hannah Linden Bob Richard
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationMultiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
More informationRelapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
Welcome to Managing Myeloma. My name is Adam Cohen, and I am the Director of Myeloma Immunotherapy and an Assistant Professor in the Hematology/Oncology Division at Abramson Cancer Center of the University
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives Discuss use of standard myeloma therapies when used as therapy
More informationJefferies 2017 Healthcare Conference
Jefferies 2017 Healthcare Conference June 9, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The
More informationThe Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma
Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 1, August 13, 2015 Antibodies: The Body s Foot Soldiers in the Battle Against Disease Speakers Moderator: Joseph Mikhael,
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationDaratumumab for multiple myeloma: A journey from phase 1 towards approval for marketing
Daratumumab for multiple myeloma: A journey from phase 1 towards approval for marketing Torben Plesner, MD University of Southern Denmark & Vejle Hospital Summary Multiple myeloma is a rare hematological
More informationSafety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed, or Relapsed and Refractory Multiple Myeloma
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed, or Relapsed and Refractory Multiple Myeloma Torben Plesner 1, Hendrik-Tobias Arkenau 2, Henk M Lokhorst 3, Peter Gimsing
More informationMultiple Myeloma Research Consortium Clinical Trial Pipeline
Multiple Myeloma Research Consortium Clinical Trial Pipeline Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk
More informationAffimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated;
More informationThe Early Chimeric Antigen Receptor (CAR) T-cell Experience From An Academic Perspective. CARs: LEARNING TO DRIVE
The Early Chimeric Antigen Receptor (CAR) T-cell Experience From An Academic Perspective CARs: LEARNING TO DRIVE Jakub Svoboda, MD University of Pennsylvania Philadelphia, PA Cancer Drug Development Forum
More informationPHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; MARTIN WERMKE 2 ; JOHN KAUH 3 ; JONATHAN BACK
More informationPHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF SINGLE-AGENT BISPECIFIC ANTIBODY T CELL ENGAGER GBR 1342 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA JOSHUA RICHTER 1 ; OLA LANDGREN 2 ; JOHN KAUH 3 ; JONATHAN BACK
More informationImmuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma
Immuno-Oncology Opportunities and Challenges In Moving Toward a Cure for Multiple Myeloma Stanley R. Frankel, MD, FACP Corporate Vice President, Clinical R & D Head, Immuno-Oncology Celgene Cancer Progress
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More informationRACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY)
RACING TOWARD A CURE FOR BLOOD CANCERS WITH NEW CARS (CAR-T CELL THERAPY) Larry D. Anderson, Jr, MD, PhD Internal Medicine Grand Rounds University of Texas Southwestern Medical Center March 9, 2018 This
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationSalvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
More informationMultiple Myeloma at ASH Kevin Song MD, FRCPC Vancouver General Hospital Leukemia/BMT Program of BC Vancouver, British Columbia
Multiple Myeloma at ASH 2017 Kevin Song MD, FRCPC Vancouver General Hospital Leukemia/BMT Program of BC Vancouver, British Columbia Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy:
More informationAbridged version of ASCO presentation June 4, 2012, for Genmab.com/investors
Abstract #809 Daratumumab a CD38 mab for the Treatment of Relapsed /Refractory Multiple Myeloma Patients: Preliminary Efficacy Data from a Multicenter Phase I/II Study Torben Plesner, Vejle Hospital, Denmark;
More informationNovel Targets in Multiple Myeloma
Novel Targets in Multiple Myeloma Ajai Chari, MD Abstract Despite the availability of 5 classes of drugs for the treatment of multiple myeloma (MM), the disease remains incurable in most cases, with patients
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationAdvances in Multiple Myeloma
Advances in Multiple Myeloma Dates of Certification: August 21, 2015, to August 21, 2016 Medium: Print with online posttest, evaluation, and request for credit Medical Writer Cheryl Zigrand Disclosure:
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationUPDATED IN HEMATOLOGIC MALIGNANCIES
UPDATED IN HEMATOLOGIC MALIGNANCIES EKAPUN KAROOPONGSE MD DIVISION OF HEMATOLOGY, MEDICINE MAHIDOL UNIVERSITY TREATMENT IN HEMATOLOGIC MALIGNANCIES Chemotherapy Immunotherapy Monoclonal antibody therapies
More informationInnovating Antibodies, Improving Lives. 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019
Innovating Antibodies, Improving Lives 37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation contains forward looking statements. The words believe,
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationImmunotherapy in myeloma
Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationThis talk will cover. New insights and future directions. Dr Hannah Hunter Consultant Haematologist University Hospitals Plymouth NHS Trust
This talk will cover New insights and future directions Dr Hannah Hunter Consultant Haematologist University Hospitals Plymouth NHS Trust An overview of current research areas o Understanding who gets
More informationGenmab Announces U.S. FDA Approval of DARZALEX (daratumumab) for Relapsed Multiple Myeloma and Updates Financial Guidance
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for relapsed or refractory multiple myeloma Financial
More informationNovel Targets in Multiple Myeloma
MULTIPLE MYELOMA Novel Targets in Multiple Myeloma Douglas Tremblay, MD, and Ajai Chari, MD Abstract Despite the availability of 6 classes of drugs for the treatment of multiple myeloma (MM), the disease
More informationIs Lenalidomide, in Combination with Dexamethasone, a Safe and Effective Treatment for Relapsed Multiple Myeloma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Lenalidomide, in Combination with
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationIMMUNOTHERAPEUTIC INTERVENTION INTO MYELOMA THERAPY
IMMUNOTHERAPEUTIC INTERVENTION INTO MYELOMA THERAPY Yi Lin, MD, PhD Consultant, Department of Internal Medicine Consultant, Department of Laboratory Medicine and Pathology Associate Professor, Medicine
More informationCombined Treatments and Clinical Trials for Better Outcomes in Multiple Myeloma
Combined Treatments and Clinical Trials for Better Outcomes in Multiple Myeloma AZMN Patient Conference March 23, 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD,
More informationReview Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Review Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma Shih-Feng Cho 1,2,3, Liang Lin 3, Lijie Xing 3,4, Tengteng Yu 3, Kenneth Wen 3, Kenneth C. Anderson 3 and Yu-Tzu Tai 3, * 1
More informationWhat do you do, with an M protein?
What do you do, with an M protein? Cancer Day for Primary Care Emily Rimmer MD FRCPC January 31, 2014 emily.rimmer@cancercare.mb.ca Disclosure of Potential for Conflict of Interest Name of presenter: Emily
More informationCAR T CELL THERAPY FOR MYELOMA MAUNG MYO HTUT, MD
CAR T CELL THERAPY FOR MYELOMA MAUNG MYO HTUT, MD Disclosures I do not have anything to disclose CAR T cell targets in multiple myeloma (MM) Targets Rationale Trials CD19 Kappa CD138 BCMA CS1 (SLAMF7)
More informationA Caregiver s Guide to Helping Myeloma Patients. Webinar 1, February 23, 2017 The New Normal for Caregivers of Patients With Multiple Myeloma
A Caregiver s Guide to Helping Myeloma Patients The New Normal for Caregivers of Patients With Multiple Myeloma Speakers Moderator: Mary DeRome Multiple Myeloma Research Foundation Norwalk, Connecticut
More informationMultiple myeloma Forecast DMKC Published on 07/04/2016
Multiple myeloma Forecast DMKC0157485 Published on 07/04/2016 Datamonitor Healthcare forecasts that the extended indications for these drugs will lead to considerable uptake across the treatment algorithm,
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Transformed Pre- Ig Surface Surface Secreted B- ALL Macroglobulinemia Myeloma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationClinical Trials in Multiple Myeloma in Arizona: Past, Present and Future
Clinical Trials in Multiple Myeloma in Arizona: Past, Present and Future AZMN Roundtable March 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Staff
More informationGSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma
GSK 916: anti-bcma ADC An exciting potential advance in the treatment of Multiple Myeloma 12 December 2017 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking
More informationImmunotherapy in Hemato-Oncology
ESMO Preceptorship Programme Immuno-Oncology From tumor immunology to clinical application 2-3 November 2016 Zurich - CH Immunotherapy in Hemato-Oncology Markus G. Manz Klinikdirektor Hämatologie USZ Leiter
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationTreatment of Multiple Myeloma with Stem Cell Transplantation (SCT)
Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA
More informationTRANSCRIPT Understanding Next in Class Novel Therapies in Multiple Myeloma: New Classes and Targets
Welcome and Introductions [Slide 1] Thank you so much. Hello everyone and thank you so much for joining us. [Slide 2] This is Joan Levy, and I am the Vice President of Research for the Multiple Myeloma
More informationControl Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design!
Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design! Marjorie Shapiro Office of Biotechnology Products/FDA WCBP 2017 January 25, 2017 Disclaimer The views presented
More informationPrincess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been
More informationacute leukemia precursor chronic leukemia lymphoma
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated t d Pre- B-cell B-cell Ig Surface Transformed B-cell Surface Plasma cell Secreted Major malignant counterpart
More informationMULTIPLE MYELOMA. on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple
MULTIPLE MYELOMA SANDRA E. KURTIN, RN, MS AOCN, ANP-C Our next session is on New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma. Pleased to have here with us today, Ms.
More informationMultiple myeloma breakthrough 2018
Multiple myeloma breakthrough 2018 Carfilzomib Can Lead to Cardiovascular Toxicity in Multiple Myeloma Patients. Get the latest science news with ScienceDaily's free email newsletters, updated daily and
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationNew Drugs and Novel Mechanisms of Action in Treating Patients With Multiple Myeloma
New Drugs and Novel Mechanisms of Action in Treating Patients With Multiple Myeloma Charise Gleason, MSN, NP-BC, AOCNP Jonathan Kaufman, MD The Winship Cancer Institute of Emory University Learning Objectives
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationKaryopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress
August 4, 2016 Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma On Track to
More informationChanging Lives. Daniel Junius, President and CEO June 3, Nasdaq: IMGN
Changing Lives Daniel Junius, President and CEO June 3, 215 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These
More informationAnti-CD38 and anti-slamf7: the future of myeloma immunotherapy
Expert Review of Hematology ISSN: 1747-4086 (Print) 1747-4094 (Online) Journal homepage: http://www.tandfonline.com/loi/ierr20 Anti-CD38 and anti-slamf7: the future of myeloma immunotherapy Elena Zamagni,
More informationGli anticorpi monoclonali nel mieloma multiplo. Management degli anticorpi in pratica clinica
Gli anticorpi monoclonali nel mieloma multiplo Management degli anticorpi in pratica clinica Elena Zamagni Seràgnoli Institute of Hematology Bologna University School of Medicine Bologna, Italy Managing
More informationASH 58 th Annual Mee/ng & Exposi/on. San Diego, CA December 3 6, 2016
ASH 58 th Annual Mee/ng & Exposi/on San Diego, CA December 3 6, 2016 Selinexor and Low Dose Dexamethasone (Sd) in Pa6ents with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib & an6-cd38 mab Refractory
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm Myeloma 101: Disease Overview Craig Emmitt Cole, MD University of Michigan Comprehensive Cancer Center What are Blood Cancers, What IS Multiple Myeloma?
More informationTranslational development of Therapeutic Lymphoma Vaccines
Translational development of Therapeutic Lymphoma Vaccines Larry W. Kwak, M.D., Ph.D. Chairman, Department of Lymphoma/Myeloma Justin Distinguished Chair in Leukemia Research Assoc. Director, Center for
More informationJ.P. Morgan Healthcare Conference. January 15, 2009
J.P. Morgan Healthcare Conference January 15, 2009 Facet Biotech Corporation Forward-looking Statements This presentation contains forward-looking statements involving risks and uncertainties and Facet
More informationJefferies Healthcare Conference
0 Jefferies Healthcare Conference 3 June 2015 NASDAQ: CRIS Forward Looking & Other Important Cautionary Statements This presentation contains forward-looking statements for purposes of the safe harbor
More informationmyeloma therapy? POINT-COUNTERPOINT POINT Should minimal residual disease negativity be the end point of Kenneth C. Anderson
POINT-COUNTERPOINT POINT Should minimal residual disease negativity be the end point of myeloma therapy? Kenneth C. Anderson Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA This
More informationA Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre
A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre April 2013 Table of Contents 1 Introduction 2 Your Support 3 Thank you 10 The Princess Margaret
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationCORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER March 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements
More informationPress Release. RedHill Biopharma Announces Phase Ib/II Study with YELIVA Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center
Press Release RedHill Biopharma Announces Phase Ib/II Study with YELIVA Initiated for Multiple Myeloma at a Leading U.S. Academic Medical Center The Phase Ib/II clinical study is intended to evaluate the
More informationUNUM THERAPEUTICS CORPORATE PRESENTATION APRIL 2019
UNUM THERAPEUTICS CORPORATE PRESENTATION APRIL 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks,
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationJP Morgan Healthcare Conference January 2019
Targeting Disease at the Nuclear Pore JP Morgan Healthcare Conference January 209 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within
More informationHELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY
HELPING DELIVER LIFE-CHANGING THERAPIES HEMATOLOGY ONCOLOGY PROVIDING COMPREHENSIVE SOLUTIONS IN A COMPLEX ENVIRONMENT PPD IS A PARTNER WITH PROVEN CAPABILITIES THAT SUPPORT AND ADVANCE ONCOLOGY RESEARCH
More informationManagement of Multiple Myeloma: The Changing Paradigm. Clinical Trials
Management of Multiple Myeloma: The Changing Paradigm Clinical Trials Goal of Clinical Trials: Making Progress Against Myeloma Increase understanding of the disease Improve the way we use currently available
More informationThank you, Lizette. I d like to add my welcome to the patients, caregivers and healthcare professionals attending the program today.
WELCOME AND INTRODUCTION Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Larry Anderson for sharing his time and expertise with us
More informationFARYDAK (panobinostat) oral capsule
FARYDAK (panobinostat) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMaking Hope A Reality bluebird style. November, 2017 Nasdaq : BLUE
Making Hope A Reality bluebird style November, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The
More informationAMGEN AT ASH 2017: DEVELOPING LEADERSHIP IN BISPECIFIC THERAPIES DECEMBER 9, 2017
AMGEN AT ASH 2017: DEVELOPING LEADERSHIP IN BISPECIFIC THERAPIES DECEMBER 9, 2017 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on management s current expectations
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pr e- Transformed Ig Su rf ace Su rf ace Secre ted Myelom a
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pr e- B-ce ll B-ce ll Transformed B-ce ll Plasma cell Ig Su rf ace Su rf ace Secre ted Major malignant
More informationبسم اهلل الرمحن الرحيم
بسم اهلل الرمحن الرحيم Definition Multiple myeloma is a neoplastic plasma cell dyscrasia (PCD) that generally produced a monoclonal immunoglobulin protein, characterized by a clinical pentad: (a) anemia;
More informationVision Statement for Multiple Myeloma: Future Directions
Vision Statement for Multiple Myeloma: Future Directions Kenneth C. Anderson Abstract There has been great progress in the management and patient outcome in multiple myeloma due to the use of novel agents
More informationHEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS (CARFILZOMIB) VERSUS VELCADE (BORTEZOMIB) MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL
ONO PHARMACEUTICAL CO.,LTD. Corporate Communications Mail:public_relations@ono.co.jp March 2, 2015 HEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS (CARFILZOMIB) VERSUS VELCADE (BORTEZOMIB) MET PRIMARY ENDPOINT
More informationPre-ASH POV: Efficient Clinical Trial and Approval Strategies in Oncology
Pre-ASH POV: Efficient Clinical Trial and Approval Strategies in Oncology A PRECISION PERSPECTIVE A Pre- ASH POV: Efficient Clinical Trial and Approval Strategies in Oncology Gerald L. Messerschmidt, MD,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus
More informationManaging Your Myeloma
Managing Your Myeloma Managing Your Myeloma Craig Emmitt Cole, MD Assistant Professor of Internal Medicine Multiple Myeloma and Plasma Cell Dyscrasia Program Division of Hematology/Oncology University
More informationGENE EDITED CAR-T THERAPIES THE PARADIGM IN ONCOLOGY
GENE EDITED CAR-T THERAPIES THE PARADIGM IN ONCOLOGY Cellectis, March 2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION CONTAINS FORWARD- LOOKING STATEMENTS THAT ARE BASED ON OUR MANAGEMENT S CURRENT
More informationJune 2017 CORPORATE OVERVIEW NASDAQ: GLYC. Innovation Today, Healing Tomorrow.
June 2017 CORPORATE OVERVIEW NASDAQ: GLYC Innovation Today, Healing Tomorrow. Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationFunction, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking
Function, Action and Interference of Anti-CD38 (DARA) Antibody in Blood Banking Joy Gould BB(ASCP)C, SBB, CQIA(ASQ), CPHQ Thomas Jefferson University Hospital Philadelphia, PA Objectives Define Multiple
More informationGalena Biopharma, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTherapeutic monoclonal antibodies & blood transfusion Essential information for hospital transfusion laboratories, transfusion practitioners &
Therapeutic monoclonal antibodies & blood transfusion Essential information for hospital transfusion laboratories, transfusion practitioners & haematology clinical teams March 2018 Background Targeted
More informationClinical Trials. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding Clinical Trials u-clintrials_en_2018_l5 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada) 818.487.7455
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More information